Which Patients Benefit From Endocrine Therapy Beyond 5 Yrs? Which Patients Benefit From Endocrine Therapy Beyond 5 Yrs?
Japanese investigators identified a group of patients with breast cancer who demonstrated improved long-term outcomes on endocrine therapy beyond the usual 5 years.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 12, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
No Added Benefit From Chemo in This Breast Cancer Subtype No Added Benefit From Chemo in This Breast Cancer Subtype
Adding chemotherapy to endocrine therapy for women with ER-positive, HER2-negative invasive lobular carcinoma does not improve survival outcomes.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 28, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Can Younger Postmenopausal Women With BC Skip Radiation? Can Younger Postmenopausal Women With BC Skip Radiation?
Women aged 65-70 years old are often offered the option of skipping radiation after lumpectomy for hormone receptor –positive early-stage breast cancer and moving straight to endocrine therapy.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 8, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Is Omitting Radiation Therapy in Low-Risk Breast Cancer a Good IDEA?
(MedPage Today) -- SAN ANTONIO -- Postmenopausal women with genomically low-risk early hormone receptor (HR)-positive breast cancer had a low risk of recurrence with endocrine therapy alone after lumpectomy, a randomized trial showed.
The 5... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 8, 2023 Category: Hematology Source Type: news
Roche ’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1The inavolisib combination has the potential to address resistance to treatment and poor prognosis associated with PIK3CA mutations2-5These new data are being presented today in an oral presentation at the 2023 San Antonio Breast Cancer Symposium and shared with health authoritiesBasel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance ®) and fu...
Source: Roche Media News - December 8, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1The inavolisib combination has the potential to address resistance to treatment and poor prognosis associated with PIK3CA mutations2-5These new data are being presented today in an oral presentation at the 2023 San Antonio Breast Cancer Symposium and shared with health authoritiesBasel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance ®) and fu...
Source: Roche Investor Update - December 8, 2023 Category: Pharmaceuticals Source Type: news
SABCS: Positive Outcomes Seen When Pausing Endocrine Therapy to Become Pregnant
THURSDAY, Dec. 7, 2023 -- Among patients with hormone receptor-positive breast cancer who paused endocrine therapy (ET) to become pregnant, fertility preservation and/or assisted reproductive technologies (ART) do not adversely affect three-year... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 7, 2023 Category: Pharmaceuticals Source Type: news
Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Phase III (INAVO120) results show that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line settingPIK3CA mutations, found in approximately 40% of HR-positive breast cancers, are linked to tumour growth, disease progression, and treatment resistance1,2Data will be shared with health authorities and presented at an upcoming medical meetingBasel, 5 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance ®) a...
Source: Roche Media News - December 5, 2023 Category: Pharmaceuticals Source Type: news
Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Phase III (INAVO120) results show that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line settingPIK3CA mutations, found in approximately 40% of HR-positive breast cancers, are linked to tumour growth, disease progression, and treatment resistance1,2Data will be shared with health authorities and presented at an upcoming medical meetingBasel, 5 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance ®) a...
Source: Roche Investor Update - December 5, 2023 Category: Pharmaceuticals Source Type: news
Long-Term Benefits of Adjuvant Abemaciclib in Breast Cancer Long-Term Benefits of Adjuvant Abemaciclib in Breast Cancer
Adding the CDK4/6 inhibitor to endocrine therapy among women with high-risk early breast cancer continues to show modest but clinically significant benefits 5 years in, compared with endocrine therapy alone.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 21, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Adhering to Endocrine Therapy Is Hard. What Can Be Done? Adhering to Endocrine Therapy Is Hard. What Can Be Done?
Poor adherence to adjuvant endocrine therapy remains an issue among patients with breast cancer. What can oncologists and patients do to improve long-term use?Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - September 25, 2023 Category: Drugs & Pharmacology Tags: Hematology-Oncology News Source Type: news
Interventions Can Increase Adjuvant Endocrine Treatment Adherence
THURSDAY, Sept. 14, 2023 -- Lowering medication costs and some psychosocial and reminder interventions show the most promise for promoting adjuvant endocrine therapy (AET) adherence in breast cancer survivors, according to a review published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 14, 2023 Category: Pharmaceuticals Source Type: news
Low Recurrence Seen With Omission of Radiation in Some Breast Cancer Cases
THURSDAY, Aug. 17, 2023 -- The incidence of local recurrence at five years is low among women aged at least 55 years with T1N0, grade 1 or 2, luminal A breast cancer who were treated with breast-conserving surgery and endocrine therapy without... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 17, 2023 Category: Pharmaceuticals Source Type: news
Higher Risk of Death With Endocrine Therapy Nonadherence Higher Risk of Death With Endocrine Therapy Nonadherence
Women with early-stage hormone receptor –positive breast cancer who do not adhere or persist with adjuvant endocrine therapy have a higher risk of relapse or mortality, a new analysis suggests.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 12, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Endocrine Therapy Plus Targeted Agents in MBC Endocrine Therapy Plus Targeted Agents in MBC
Endocrine therapy remains the mainstay of treatment in metastatic breast cancer. Dr Erica Mayer discusses adding targeted agents as clinicians strive to improve therapeutic options and efficacy.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 28, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Article Source Type: news
